Stock Report

Eris Lifesciences Ltd announces Strategic Partnership with Natco Pharma Ltd for Semaglutide Launch in India

Posted On : 2026-02-24 15:38:51( TIMEZONE : IST )

Eris Lifesciences Limited ("Eris Lifesciences" or the "Company") (BSE: 540596; NSE: ERIS), a leading Indian branded formulations company, recently announced a strategic partnership with Natco Pharma Limited for the commercialisation of Semaglutide in India, reinforcing Eris's commitment to expanding its leadership in the fast-growing diabetes and metabolic care segment.

Semaglutide, a GLP-1 receptor agonist, has emerged globally as a transformative therapy in the management of Type 2 diabetes and chronic weight management driven by robust clinical outcomes in glycemic control and weight reduction. With India witnessing a rapidly growing diabetic population and increasing awareness around obesity management, GLP-1 therapies represent a high-growth opportunity within the metabolic segment.

Eris has built a strong and scalable presence in diabetology over the years, supported by a wide specialist reach and deep engagement with endocrinologists, diabetologists and physicians across India. The addition of semaglutide is expected to further strengthen Eris' portfolio in advanced diabetes therapies and enhance its participation in next-generation metabolic treatments.

This collaboration builds on both companies' complementary strengths: Eris's robust commercial and diabetes franchise presence, and Natco's manufacturing and regulatory prowess in complex formulations.

Strategic Partnership Details

Regulatory Milestone: Natco Pharma has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture generic semaglutide for the Indian market, paving the way for a launch expected in March 2026.

Market Focus: The product will target Type 2 diabetes management aligning with unmet needs in India's expanding metabolic care landscape.

Mr. Amit Bakshi, Chairman & Managing Director, Eris Lifesciences Ltd, said: "Semaglutide represents one of the most significant therapeutic advances in metabolic care in recent years. This partnership reflects our continued commitment to strengthening our diabetes franchise with innovative and high-impact therapies. With our strong commercial infrastructure and deep engagement in chronic therapies, we believe Eris is well positioned to drive rapid adoption and enhance patient access in India."

He further added that Eris has been proactively preparing its commercial strategy to participate meaningfully in the GLP-1 opportunity and views this partnership as a long-term value driver for the company.

Shares of Eris Lifesciences Limited was last trading in BSE at Rs. 1351.35 as compared to the previous close of Rs. 1342.10. The total number of shares traded during the day was 1007 in over 160 trades.

The stock hit an intraday high of Rs. 1355.80 and intraday low of 1330.05. The net turnover during the day was Rs. 1348278.00.